Thienopyridine-Associated Thrombotic Thrombocytopenia Purpura: Updated Antibody Results From the SERF-TTP Study.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 892-892
Author(s):  
Anaadriana Zakarija ◽  
Thanh Ha Luu ◽  
Hau C. Kwaan ◽  
June McKoy ◽  
Ivy Weiss ◽  
...  

Abstract Abstract 892 Background: The thienopyridines, ticlopidine and clopidogrel, have been associated with thrombotic thrombocytopenia purpura (TTP). However, few studies have reported information on antibodies to ADAMTS13 among patients with thienopyridine-associated TTP. We previously reported on two mechanistic pathways of thienopyridine-associated TTP with some overlapping features. Evaluation of ADAMTS13 autoantibodies was undertaken to improve understanding of these syndromes. Methods: Clinical and laboratory findings were evaluated for 30 ticlopidine-, 10 clopidogrel-associated TTP cases, and 54 cases of idiopathic TTP. Results: Among patients with thienopyridine-induced TTP, those with a history of ticlopidine versus clopidogrel use were more likely to present with severe thrombocytopenia (platelet < 20,000) (90% versus 13%), severe ADAMTS13-deficiency (80% versus 0%), and neutralizing antibodies to ADAMTS13 (100% versus 0%), and were less likely to have less than a two week history of thienopyridine exposure (0% versus 50%) (p<0.05 for each comparison). They were also more likely to survive following therapeutic plasma exchange (TPE) (85% versus 50%). 2 patients exposed to clopidogrel later relapsed and had similar characteristics to idiopathic TTP patients with non-deficient ADAMTS13 activity. Conclusion: Ticlopidine causes TTP by a pathway involving a neutralizing autoantibody to ADAMTS13 while clopidogrel causes TTP by an ADAMTS13-independent pathway. Although ADAMTS13 autoantibodies are present in both idiopathic and ticlopidine-associated TTP, spontaneous relapses are not seen in ticlopidine-associaated TTP, suggesting that drug-dependent antibodies are present. Clopidogrel associated TTP is distinct from idiopathic TTP in that ADAMTS13 autoantibodies are absent and response to TPE is poor. Disclosures: No relevant conflicts of interest to declare.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 2088-2088 ◽  
Author(s):  
Charles L. Bennett ◽  
Thanh Ha Luu ◽  
Anaadriana Zakarija ◽  
Hau C. Kwaan ◽  
Nicholas Bandarenko ◽  
...  

Abstract Background: Thrombotic thrombocytopenic purpura (TTP) is a rare disorder that presents with microangiopathic hemolytic anemia and thrombocytopenia, fevers, renal insufficiency and neurologic features. We reviewed clinical, laboratory, and outcome data for TTP cases with severely deficient versus non-severely deficient ADAMTS13 activity levels. Methods: Mean and median data were from the Surveillance, Epidemiology and Risk Factors for TTP (SERF-TTP) study group for idiopathic TTP cases, the Canadian Apheresis Group (CAG), and five published series (Zheng 2004, Raife 2004, Vesely 2003 (Oklahoma TTP-HUS Registry), Matsumoto 2004 (Japan Referral Center), Bennett 2007). Results: Compared to TTP cases with near-normal ADAMTS13 activity levels (n= 282), TTP cases with severe ADAMTS13-deficiency (n=185) were more likely to have severe thrombocytopenia, normal renal function and neutralizing ADAMTS13 antibodies. Severe ADAMTS13 deficient TTP cases have better overall survival after therapeutic plasma exchange (TPE) but are more likely to relapse. TTP patients with severe ADAMTS13 deficiency were primarily categorized as idiopathic or ticlopidine-associated, while TTP patients with non-severely deficient ADAMTS13 activity levels were frequently categorized as idiopathic, secondary to drugs (clopidogrel, quinine), stem cell transplantation, or cancer. Conclusions: Severe ADAMTS13 deficiency is most commonly idiopathic, has better survival following TPE, and a 35–40% spontaneous relapse rate. By contrast, non-ADAMTS13 deficient TTP cases are usually associated with an underlying disorder or external insults. Amongst this cohort, four series have 47–62% survival rates and three series, which contain mostly idiopathic cases, have 83–90% survival rates following TPE. From this, we propose that TTP may occur by three possible mechanism; ADAMTS13-deficient (antibody-mediated), an immunologic mediated pathway independent of ADAMTS13 (i.e. quinine) that is responsive to TPE, and endothelial injury related TTP that is unresponsive to TPE. Platelet count mean (x10^9/L) Creatinine mean (mg/dl) ADAMTS13 neutralizing antibodies (%) Survival % Relapse % * &lt;15% ADAMTS13 activity cutoff Severe ADAMTS13 Deficiency (&lt;10–15%) SERF-TTP (n=30) 19 1.3 83 97 41 Zheng (n=16) 19 1.6 44 81 38 Bennett (n=26) 15 85 Oklahoma (n=18) 12 1.8 94 81 38 Raife (n=50) * 13 1.2 92 35 Japan (n=34) 35 91 Canada (n=11) 16 2.4 82 Not Severely Deficient ADAMTS13 Activity (&gt; 15%) SERF-TTP (n=22) 57 3.9 35 90 0 Raife (n=57) * 44 2.7 83 9 Canada (n=17) 57 4.1 88 Zheng (n=13) 40 3.0 0 54 Bennett (n=13) 62 Japan (n=66) 9 62 Oklahoma (n=94 ) 23 47 3


Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 4193-4193
Author(s):  
Ang Li ◽  
Pavan K Bendapudi ◽  
Ayad Hamdan ◽  
Robert S Makar

Abstract Introduction: The ADAMTS13 assay is routinely ordered as part of the work-up for thrombotic microangiopathies (TMAs). While severe deficiency of ADAMTS13 activity (≤10%) is specific for the diagnosis of idiopathic TTP and identifies a group of patients who respond well to treatment with therapeutic plasma exchange (TPE), the implications of mild-to-moderate deficiency (11-66%) remain unclear. This study aims to elucidate the presenting characteristics, clinical outcomes and diagnoses, and responses to TPE in TMA patients with non-critically low ADAMTS13 activity. Methods: Two hundred-fifty two adult TMA patients from 3 large academic medical centers over a 10-year period were identified based on the presence of microangiopathic hemolytic anemia (schistocytes on smear, platelets <150,000/μL) and available ADAMTS13 results. Sixty-eight patients with ADAMTS13 ≤10% were excluded from the current analysis. Three cohorts were identified from the remaining 184 patients based on their ADAMTS13 activity level: 45 moderately deficient (11-40%), 84 mildly deficient (41-66%), and 55 non-deficient (≥67%). The ANOVA and chi-square tests were used for intergroup comparisons. Kaplan-Meier curves with log-rank analysis were used to assess survival differences where day 0 was defined as the day ADAMTS13 assay was sent. Results: With the exception of younger age in the non-deficient group, the 3 cohorts were similar with respect to gender and ethnicity, presenting signs and symptoms, clinical history and laboratory values (Table 1). Whereas the frequency of secondary TMA attributable to drugs, malignancy, hypertension, hemolytic-uremic syndrome (HUS), and autoimmune disease was not different across these three cohorts, patients with moderate reduction in ADAMTS13 activity were more likely to have disseminated intravascular coagulation (DIC) and sepsis compared to the mildly- and non-deficient cohorts (p=0.001). Additionally, the moderately deficient cohort had slower recovery of platelet count by day 4 (p=0.043) and significantly lower 90-day survival (Figure 1, p=0.01 by log-rank). The role of TPE in patients with moderate ADAMTS13 deficiency was evaluated. TPE was performed in 10 of 45 patients (22%). Presenting features among these 10 patients were not significantly different from the 33 patients (73%) who did not receive TPE (2 patients receiving <3 treatments were excluded). The 90-day survival between these two subgroups was not significantly different (Figure 2, p=0.48 by log-rank). Conclusions: Moderate ADAMTS13 deficiency (11-40%) in patients with TMA is more frequently associated with an underlying diagnosis of DIC and sepsis and portends slower recovery as well as worse survival. A modest reduction of ADAMTS13 activity may be a result of disease manifestation rather than the cause. Therefore, therapy directed at the underlying disease processes may lead to better outcomes than routine plasma exchange for these patients. Figure 2 Figure 2. Figure 3 Figure 3. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 2090-2090
Author(s):  
Karen K. Swisher ◽  
Qurana F. Lewis ◽  
Judith A. James ◽  
Johanna A. Kremer Hovinga ◽  
Bernhard Lämmle ◽  
...  

Abstract Patients who have TTP associated with acquired, severe ADAMTS13 deficiency have an autoimmune etiology and therefore may have increased risk for additional autoimmune disorders. The Oklahoma TTP-HUS Registry enrolled 247 consecutive patients with their first episode of clinically diagnosed TTP from 11-13-1995 (the date of our initial ADAMTS13 measurement) to 6-30-2006 for whom plasma exchange treatment was requested; ADAMTS13 activity was measured in 228 (92%) of patients immediately before their first plasma exchange treatment; 42 (18%) patients had ADAMTS13 activity &lt;10%. Three patients were excluded from this analysis because of preexisting systemic rheumatic disease (systemic lupus erythematosus (SLE), 2, Sjogren’s syndrome, 1). To examine the potential risk for development of autoimmune disorders, we measured screening autoantibodies (ANA, dsDNA, Sm, nRNP, Ro, La, ribosomal P, Jo-1, anti-phospholipid (aPL) IgG and IgM) in 34 of the 39 (87%) remaining patients. The median age at initial presentation was 39 years (range 9–71 years); 27 (79%) patients were women; 13 (41%) patients were black. Autoantibodies were measured by indirect immunofluorescence, immunodiffusion, or ELISA. Measurements were performed only once in 16 patients; in 18 patients 2–3 measures were performed over a period of 13 to 126 months. Rheumatic disease autoantibodies TTP patients *1 patient had a maximum titer of &gt;1:3240 in 2 samples; 1 patient developed overt SLE and his titer decreased with treatment. ANA ≥1:40 on at least one occasion 33/34 (97%) ANA ≥1:120 on at least one occasion 29/34 (85%) ANA measured ≥2 times, increasing titer 14/16* (88%) Anti-dsDNA ≥1:30 12/34 (35%) Anti-Ro positive 14/29 (48%) Anti-Sm positive 1/34 (3%) Anti-nRNP positive 1/34 (3%) aPL IgG and/or IgM ≥moderate positive 4/34 (12%) No patients had positive tests for anti-La, anti-Ribo-P, or anti-Jo-1. 23 (68%) of the 34 patients had a positive test for one or more rheumatic disease autoantibodies (dsDNA, nRNP, Ro, La, or moderately positive aPLs). 4 of the 34 patients died during their initial episode; the remaining 30 patients have been followed for a median of 6.4 years (range, 1–11.5 years). During this time only 1 patient has developed clinically evident SLE; no other patients have developed systemic rheumatic diseases. Conclusions: A high prevalence of rheumatic disease-associated autoantibodies were found in a cohort of consecutive patients with TTP associated with acquired severe ADAMTS13 deficiency. The presence of dsDNA and Ro autoantibodies and increasing ANA titers suggest that patients with ADAMTS13-deficientTTP may have a potential risk for developing additional autoimmune disorders such as SLE or Sjogren’s syndromes. [3] These serologic observations support clinical observations that presenting features of TTP and SLE may overlap.


Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 4555-4555
Author(s):  
Charles L. Bennett ◽  
Ari Polish ◽  
Athena T Samaras ◽  
Mi Zheng ◽  
Dennis P West ◽  
...  

Abstract Abstract 4555 Introduction HGFs have vastly improved the management of anemia, neutropenia, and thrombocytopenia, but are associated with unexpected toxicities. Methods Toxicities associated with granulocyte, erythroid, and thrombopoietic growth factors were reviewed. Data sources included systematic reviews, clinical trials, guidelines, and materials disseminated by the Food and Drug Administration (FDA), the European Medicines Agency (EMEA), and Canada Health and their advisory committees; product labels and safety notifications disseminated by manufacturers; and utilization data. Data abstracted were thromboembolic complications, immune-mediated cytopenias, bone marrow toxicities, systematic and synergistic toxicities, and regulatory responses. Results Granulopoiesis agents Pulmonary infiltrates were associated with administration of HGFs with bleomycin or chest radiation. Increased myelodysplasia (MDS) or acute myeloid leukemia (AML) risks among chemotherapy (chemo)-treated breast cancer patients were reported. ESAs Increased mortality and tumor progression were seen when cancer patients received ESAs versus placebo; increased mortality and cardiovascular events were reported when chronic kidney disease (CKD) patients received ESAs targeted to complete anemia correction. Between 1998 and 2003, 191 CKD patients developed neutralizing antibodies and pure red cell aplasia (PRCA) following recombinant erythropoietin administration. Thrombopoietins (TPO) TPO receptor agonist administration is associated with bone marrow reticulin and collagen deposition. 3% of healthy volunteers who received repeated rHuMGDF developed neutralizing autoantibodies and severe thrombocytopenia. Conclusions While ESAs, granulopoietic factors, and thrombopoietins have important clinical benefits, they also retain the potential to exhibit serious and unanticipated toxicities. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 2519-2519
Author(s):  
Deirdra R. Terrell ◽  
Zayd Al-Nouri ◽  
Judith A. James ◽  
Johanna A. Kremer Hovinga Strebel ◽  
Bernhard Lämmle ◽  
...  

Abstract Abstract 2519 TTP associated with acquired, ADAMTS13-deficiency and SLE are both autoimmune disorders that occur preferentially in young, black women and they have many similar clinical features. TTP may occur in patients previously diagnosed with SLE, or patients may develop SLE following recovery from TTP. In addition, TTP may be quite difficult to distinguish from SLE patients with severe hematologic manifestations. We compared the prevalence of SLE-associated autoantibodies in TTP patients to published population data using 95% confidence intervals (CI). The Oklahoma TTP Registry enrolled 292 consecutive patients with their first episode of clinically diagnosed TTP from 11–13-1995 (date of our initial ADAMTS13 measurement) to 7–31-2009; ADAMTS13 activity was measured in 271 (93%) patients; 64 (24%) patients had ADAMTS13 activity <10%, 63 were evaluated for SLE-associated autoantibodies, including 2 patients with a previous diagnosis of SLE. Serum from the patient's acute initial episode was used for analysis. The prevalence of ANA, anti-dsDNA, anti-Ro, and aPL in TTP patients was significantly higher than published population data; prevalences of anti-nRNP, anti-Sm, and anti-La were not different. Autoantibody TTP (95% CI) Population % ANA  ≥1:40 89% (78%–95%) 0–27%  ≥1:120 56% (42%–68%) 0% Anti-dsDNA  ≥1:30 43% (30%–56%) 3% Anti-Ro  OD>0.350 17% (8%–29%) 3% aPL IgM  ≥20 PL units 15% (7%–26%) 2% Because of the increased prevalence of SLE-associated autoantibodies, we evaluated our TTP patients for the America College of Rheumatology (ACR) criteria for SLE (presence of ≥4 of 11 criteria suggests the diagnosis of lupus); abnormalities associated with any TTP episode were not counted in this evaluation of clinical criteria for SLE. By definition ACR criteria can be fulfilled serially or simultaneously over a lifetime. Evaluations were completed between 6-1-2007 and 5-1-2009 on 38/42 (90%) eligible patients (alive, non-institutionalized, no previous SLE diagnosis) consisting of physical examination, review of available lifetime medical records, and serial laboratory evaluations. Patients have been followed for a median of 8.3 years (range, 1–14 years). During this time, 3 (8%) developed clinically evident SLE requiring treatment 1, 5, and 70 months after their initial TTP episodes. Among the other 35 patients, 3 (8%) have ≥4 SLE classification criteria by medical record review (1 had pre-existing Sjögren's syndrome and receives treatment; 2 have minimal clinical features and are not actively treated for SLE); 9 (24%) have 3 criteria; 16 (42%) have 2 criteria; 6 (16%) have 1 criterion; and 1 (2%) patient has no ACR criteria for SLE. All patients continue to be followed and clinically evaluated for potential intervention. SLE diagnosis is a clinical designation and because of the lack of disease modifying drugs, routine follow-up is standard of care unless the patient is symptomatic. Conclusions: [1] A high prevalence of SLE-associated autoantibodies was present in a cohort of consecutive patients with TTP associated with acquired severe ADAMTS13 deficiency. [2] The presence of anti-dsDNA, anti-Ro, aPL and high titers of ANA suggest that patients with ADAMTS13-deficient TTP may be at risk for developing SLE. [3] During long-term follow-up, 6 (16%) of 38 patients have developed overt SLE or ACR criteria without an established diagnosis of SLE. Careful continuing evaluation following recovery from TTP is important. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 4386-4386
Author(s):  
Eimad Zakariya ◽  
Mariko Yabe ◽  
Armistead Williams ◽  
Randy L. Levine ◽  
Mark T Friedman

Abstract Abstract 4386 Background: Progressive multifocal leukoencephalopathy (PML) associated with natalizumab in multiple sclerosis (MS) treatment is a complication for which therapeutic plasma exchange (TPE) has been used. We describe such a case treated with TPE. Case Report: A 54 year old woman with a past medical history of relapsing-remitting MS presented with recent onset ataxia and bilateral upper and lower extremity weakness and right hand dysmetria. Two weeks prior to presentation, she completed 57 treatments with natalizumab, a monoclonal antibody against cellular adhesion molecule α4-integrin that blocks lymphocytes from crossing the blood-brain barrier. Brain MRI showed new non-enhancing lesions in the right cerebellum and anterior left temporal lobe. Natalizumab was discontinued and investigation revealed high serum and CSF titers of JC virus DNA indicative of PML. The patient underwent a total of 3 TPE's (1 every other day) with 3L of 5% albumin solution (1.4 plasma volume [PV]) used as replacement each TPE. After TPE, the patient initially showed improvement of neurological function and was transferred to inpatient acute rehabilitation. However, 4 days later she suffered a seizure and developed slurred speech. MRI showed that the cerebellar lesion had extended into the pons. The patient also developed dysphagia requiring nasogastric tube feeding and poorly-localized pain requiring pain management. She was treated with steroids for possible Immune Reconstitution Inflammatory Syndrome (IRIS) and discharged to hospice care for rehabilitation and pain management. The patient's condition continued to deteriorate and she died shortly after being arriving at hospice. Conclusion: Natalizumab selectively immune suppresses the CNS putting patients at risk for PML and TPE with or without immunadsorption, can rapidly reverse the immune suppression by clearing natalizumab. Although we did not measure natalizumab concentrations in our patient, 1 report showed that a series of 3 TPE's (1.5 PV) significantly decreased natalizumab levels while another showed that 3–5 TPE's (1–1.5 PV) was effective. The effect of reducing natalizumab is to exchange the problem of a typically fatal opportunistic infection for the problem of an aggressive potentially injurious immune response to that virus. IRIS itself requires intense management to prevent brain injury or death and while there is no set standard of care, steroids are typically used. According to the manufacturer's global monitoring system, the majority of natalizumab induced PML cases are treated with TPE which typically induces IRIS within days to weeks. The most recent mortality rate for all PML cases related to this drug is 22%, significantly lower than that seen with AIDS or in the oncology setting. Although our patient initially improved after TPE, the proximity of the PML to her brainstem, with or without IRIS, made her particularly vulnerable. Whether TPE may lead to more severe IRIS, as suggested by one report, requires further study. Nevertheless, given the severe consequences of PML itself, we would recommend TPE for natalizumab -induced PML. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 5051-5051
Author(s):  
Hina Chaudhry ◽  
Michelle Sholzberg ◽  
Katerina Pavenski

Abstract Background: Thrombotic thrombocytopenic purpura (TTP) presents with microangiopathic hemolytic anemia and thrombocytopenia and is caused by severe ADAMTS13 deficiency. TTP can be the result of autoantibodies to ADAMTS13 or genetic defect in the ADAMTS13 gene. ADAMTS-13 is an enzyme that specifically cleaves unusually large von Willebrand Factor (VWF) multimers which mediate platelet thrombus formation under high shear. When ADAMTS13 is deficient, unusually large VWF multimers accumulate causing excessive platelet aggregation and thrombosis in the microvasculature. Methods: St. Michael's Hospital, Toronto is home to a large reference laboratory for special coagulation. We use a commercial ELISA Technoclone Technozym ADAMTS-13 activity assay for the determination of ADAMTS-13 activity and Technoclone Technozym ADAMTS-13 inhibitor assay to identify anti-ADAMTS-13 antibodies. We send samples to another Canadian laboratory for validation of our results as they use an in-house ELISA assay for ADAMTS13 activity and anti-ADAMTS13 antibody. Results: We performed a retrospective review of all ADAMTS13 activity tests performed by our laboratory between January 1, 2013 and June 30, 2018. The total number of tests was 466 from 203 unique patients. 24% had an ADAMTS-13 activity under 10% (N = 144) which is consistent with the diagnosis of TTP. When specimens with severe ADAMTS-13 deficiency were tested for presence of anti-ADAMTS13 antibody, 46% were negative. Four of these specimens were sent to the other laboratory and all had detectable, albeit very low titre, inhibitors. Furthermore, on repeated testing over the study period, the vast majority of patients who presented with low ADAMTS13 activity and no detectable antibody subsequently became antibody positive. Fifty-two patients remained antibody negative by our internal and send-out testing. Five of them were known to have or were subsequently diagnosed with hereditary TTP (hTTP). Only one patient continues to have negative antibody but whose clinical course is not consistent with hTTP. Conclusions: We found that a commercial ADAMTS13 (Technoclone Technozym) antibody assay is falsely negative in a substantial proportion of patients with autoimmune TTP, the majority of which likely had a low titer inhibitor, below the threshold of test detection. More sensitive assays and/or repeated testing, presumably as inhibitor titre increases during the course of the disease, may detect antibody presence in the majority of samples of patients with autoimmune TTP. This is an important finding as this could impact the types of therapies offered to patients with negative antibody screens and may also avoid unnecessary, expensive genetic testing . Disclosures No relevant conflicts of interest to declare.


Author(s):  
Morena J ◽  
◽  
Antimisiaris M ◽  
Singh D ◽  
◽  
...  

Objective: We present the distinct clinical and laboratory findings in two cases of Ehrlichia meningoencephalitis, along with one suspected case. Background: The number of cases of Ehrlichia chaffeensis reported to the CDC has more than doubled from 2007-2017. A PubMed literature search using the words “Ehrlichiosis and meningoencephalitis” revealed five case reports with neurologic manifestations. Design/Methods: This is a retrospective observational study. Two elderly patients presented with encephalopathy, fever, transaminitis, thrombocytopenia, a positive E. chaffeensis Polymerase Chain Reaction (PCR) in Serum, and Cerebrospinal Fluid (CSF) with a lymphocytic or neutrophilic pleocytosis and elevated protein. One patient had similar symptoms and a positive E. chaffeensis PCR, but lumbar puncture was unable to be performed due to severe thrombocytopenia. They presented in May or June. Doxycycline was started within 2-3 days after presentation to the hospital. Follow up five months later revealed all patients were close, or back to baseline. Results and Conclusions: Suspicion of Ehrlichia meningoencephalitis should be raised in elderly patients presenting with fever and encephalopathy in the summer season with history of tick bite or residence in wooded areas. Thrombocytopenia and transaminitis should raise further suspicion. CSF studies typically show a lymphocytic pleocytosis and elevated protein. PCR technique allows for direct detection of pathogen-specific DNA and is the preferred method of detection during the acute phase of illness. Prompt treatment with doxycycline results in good outcomes. Doxycycline is not included in the typical meningitis regimen, therefore, this disease is important to quickly identify as delay in Doxycycline can result in worse outcomes.


Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 4905-4905
Author(s):  
Phani Borra ◽  
Cory Edward Mellon

Learning Objective 1: Recognize that multiple etiologies can play a role in the overall presentation of patient's thrombocytopenia. Learning Objective 2: Rethink the original working diagnosis when there is discordance with clinical picture. Case: 52-year old male with a PMHx of heroin and alcohol abuse presented to ED after being found unresponsive due to heroin OD. Patient (Pt) was initially seen in the ED 4days prior for left leg cellulitis and was sent home on oral Bactrim. Lab values during that visit showed a platelet (plt) count of 80 K/UL, Hgb 10.1 g/dl and creatinine (Cr) of 1.46 mg/dl. On his 2nd ED visit, his WBC count was 12.7 K/UL, Hgb 7.7g/dl, plt 23K/UL, haptoglobin <8.0mg/dl and reticulocyte count of 4.1%. His BUN and Cr were elevated at 32 mg/dl and 2.97mg/dl respectively and UA showed large blood with 3-5 RBC, CPK was 24806 IU/L, LFTs demonstrated an AST of 414 IU/L, ALT of 90 IU/L, total bilirubin 2.0mg/dl, direct bilirubin 0.8mg/dl, LDH of 2339 IU/L and ESR >140 mm/hr. Coagulation parameters were normal. Pt's urine toxicology was positive for opiates and methadone. Manual differential was initially negative for schistocytes, helmet cells or bite cells. HIV was non-reactive, RPR and acute hepatitis panel were negative. On exam, pt was drowsy, had icteric sclera and faint left pedal pulses without purpuric rash. Pt was started on IV fluids for oliguric AKI and rhabdomyolysis. Arterial doppler revealed no detectable blood flow in his left distal superficial femoral, tibial and popliteal arteries. Initial CT head was negative for acute findings. Hematology consulted for possible diagnosis of TTP. Consultant didn't think clinical picture was consistent with TTP as total bilirubin at the time of consultation was normal therefore plasma exchange wasn't recommended. However, primary service still considered TTP highest on the differential therefore, ADAMTS13 was ordered but no plasma exchange was initiated. Given the fact pt received oral Bactrim for diagnosis of lower extremity cellulitis, G6PD deficiency was included in the differential however, testing was done early after hemolytic event and while reticulocytes were elevated, therefore results were not diagnostic. Of note, plts were transfused per vascular surgery prior to a planned thrombectomy of left leg, and plts increased to 81 K/UL. Pt underwent unsuccessful left leg thrombectomy due to chronic changes in the vessels and collaterals. CPK levels continued to increase and renal function continued to worsen as did his mental status. Pt was started on hemodialysis (HD) by end of 2nd day. There was persistent effort to incorporate all lab derangements into one all-inclusive diagnosis. Hematology was asked to review the case again as pt's plts continued to drop, ADAMTS13 activity was low at <2.0% and schistocytes were now noted on the peripheral smear. TTP was again not seen as the primary cause of the pt's clinical picture as total bilirubin continued to be normal, schistocytes only appeared after HD was initiated and low ADAMTS13 was thought to be secondary to liver dysfunction, inflammation and heroin OD. A repeat CT-head done showed left cerebellar hypodensities suspicious for acute CVA. Pt continued to deteriorate requiring mechanical ventilation. Troponins were checked which showed a level of 31.90ng/dl and ECG done simultaneously showed sinus tachycardia and no ischemic changes. Cardiology was consulted who determined trop elevation was likely due to skeletal muscle injury and possibly due to NSTEMI. However, due to pt's severe thrombocytopenia, Cardiology determined he was not a candidate for antiplatelet therapy or anticoagulation. Despite aggressive resuscitative measures, patient died Discussion: We reviewed the literature to evaluate other causes of this pt's clinical picture. While pt has overlapping features of TTP except fever, other causes for his mild hemolytic anemia and low plts include polysubstance abuse, rhabdomyolysis, poor nutritional status, presence of alcoholic fatty liver and uremia. Thrombocytopenia is associated with an increased risk of adverse outcomes, regardless of the causes. It has been documented in literature that heroin OD can cause rhabdomyolysis, renal failure, cardiac dysfunction, and permanent neurologic complications. The original diagnosis of TTP was anchored on and we persisted in trying to make the clinical picture fit that diagnosis and delayed in looking at overall clinical picture of the pt. Disclosures No relevant conflicts of interest to declare.


2021 ◽  
Author(s):  
Ajay Major ◽  
Timothy Carll ◽  
Clarence W. Chan ◽  
Chancey Christenson ◽  
Geoffrey D. Wool ◽  
...  

Abstract Vaccine-induced thrombotic thrombocytopenia (VITT) is a newly-described hematologic disorder which presents as acute thrombocytopenia and thrombosis after administration of adenovirus-based vaccines against COVID-19. Due to positive assays for antibodies against platelet factor 4 (PF4), VITT is managed similarly to autoimmune heparin-induced thrombocytopenia (HIT) with intravenous immunoglobulin (IVIG) and non-heparinoid anticoagulation. We describe a case of VITT in a 50-year-old man with antecedent alcoholic cirrhosis who presented with platelets of 7 × 103/µL and portal vein thrombosis 21 days following administration of the Ad26.COV2.S COVID-19 vaccine. The patient developed progressive thrombosis and persistent severe thrombocytopenia despite IVIG, rituximab and high-dose steroids and had persistent anti-PF4 antibodies over 30 days after his initial presentation. As such, delayed therapeutic plasma exchange (TPE) was pursued as salvage therapy, with a rapid and sustained improvement in his platelet count. Our case serves as proof-of-concept of the efficacy of TPE in VITT.


Sign in / Sign up

Export Citation Format

Share Document